Review
Atypical pneumonia: Pathophysiology, diagnosis, and treatment

https://doi.org/10.1016/j.resinv.2021.09.009Get rights and content

Abstract

Atypical pneumonia is caused by atypical pathogens that are not detectable with Gram stain and cannot be cultured using standard methods. The most common causative organisms of atypical pneumonia are Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella species. The therapeutic approach for atypical pneumonias is different than that for typical pneumonia. Typical bacterial pathogens classically respond to β-lactam antimicrobial therapy because they have a cell wall amenable to β-lactam disruption. On the contrary, most atypical pathogens do not have a bacterial cell wall, some are intracellular (e.g., Legionella), and some are paracellular (e.g., M. pneumoniae). To prevent an increase in the number of antimicrobial-resistant strains, the Japanese pneumonia guidelines have proposed a differential diagnosis for typical bacterial pneumonia and atypical pneumonia to select an appropriate antibiotic for the management of mild-to-moderate pneumonia. The guidelines have set up six parameters and criteria based on the clinical symptoms, physical signs, and laboratory data. However, in the elderly individuals and patients with underlying diseases, the differential diagnosis may be difficult or a mixed infection may be latent. Therefore, in these individuals, the administration of a β-lactam drug plus a macrolide or tetracycline, or only fluoroquinolone should be considered from the beginning to cover bacterial and atypical pneumonia.

Introduction

The term “atypical pneumonia” was first used to describe viral community-acquired pneumonias (CAPs) that were clinically and radiologically distinct from bacterial CAPs. The most common causative organisms of atypical pneumonia are Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella species. Other possible pathogens include Chlamydia psittaci (psittacosis), Coxiella burnetii (Q fever), and respiratory viruses such as the novel severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019).
Atypical pneumonias differ fundamentally from bacterial CAPs. However, the major feature differentiating atypical CAP from typical CAP is the presence or absence of extrapulmonary findings. All atypical pulmonary pathogens cause systemic infectious diseases with a pulmonary component (i.e., pneumonia) [[1], [2], [3], [4], [5]]. Pneumonias caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis are typical CAPs with clinical and laboratory findings limited to the lungs.
In this mini-review, I have summarized the results of atypical pneumonia obtained from a series of experiments performed over the last 30 years.

Access through your organization

Check access to the full text by signing in through your organization.

Access through your organization

Section snippets

Epidemiology

Atypical CAPs represent >15% of all CAPs; however, their incidence varies with location [[6], [7], [8], [9], [10], [11], [12], [13]]. Atypical pathogens causing pneumonia may also cause outbreaks of nursing and healthcare associated pneumonia (NHCAP) and hospital-acquired pneumonia (HAP) [14]. However, the occurrence of atypical pneumonia pathogens causing NHCAP or HAP is rare [[15], [16], [17]].
Atypical CAP pathogens, particularly M. pneumoniae and C. pneumoniae, cause the majority of CAPs in

Morphological analysis of C. pneumoniae

Chlamydiae, obligate intracellular parasites, depend on the biosynthetic machinery of the host cells for several metabolic functions. All chlamydiae multiply through a common, unique developmental cycle involving two morphologically and functionally distinct forms: one is the infectious elementary body (EB) and the other is the reproductive reticulate body (RB). Morphologically, EBs have a high density and are small in size (diameter: 0.3–0.35 μm), whereas RBs consist of rather homogeneous

Clinical presentation

Although pneumonia caused by M. pneumoniae, C. pneumoniae, and SARS-CoV-2 is usually a benign, self-limited disease, some cases are known to develop into refractory or severe, life-threatening pneumonia [[35], [36], [37]]. On the contrary, pneumonia caused by Legionella often presents as a rapidly progressive, severe pneumonia. Legionella CAP has a high mortality rate of approximately 10%, which may increase up to 27% in patients who do not receive adequate antibiotics as a part of their

Particle counting method

I established a method to purify the EBs of all chlamydial species (Fig. 6) [48]. Additionally, they established a method for counting the number of EBs under a scanning electron microscope after sedimentation of EBs on a coverslip by centrifugation. A series of purified EBs are prepared by 2- or 10-fold serial dilution based on the number of EBs. Thereafter, EBs are assayed with antigen or gene detection assay to compare the number of EBs at the detection limit (cutoff level) of each test kit.

In vitro and in vivo activity

A different therapeutic approach is required for atypical pneumonias require compared with typical CAPs. Typical bacterial pathogens classical respond to β-lactam antimicrobial therapy because they have a cell wall amenable to β-lactam disruption. On the contrary, most of the atypical pathogens do not have a bacterial cell wall, some are intracellular, (e.g., Legionella), and others are paracellular (e.g., M. pneumoniae).
Antimicrobials that inhibit or eradicate microorganisms by interfering

Conflict of Interest

The author has no conflict of interest.

Acknowledgments

I am very grateful to Professor Rinzo Soejima. Toshiharu Matsushima, Akira Matsumoto, Cho-chou Kuo, Yoshihito Niki and Niro Okimoto for leading. I wish to thank members of the Atypical Pathogen Study Group for providing details of infections caused by atypical pathogens. I also wish to thank members of the Treatment Evaluation Committee for Legionella in Japanese Society for Chemotherapy. This study was supported in part by MEXT KAKENHI (19591190 and 21591304) and Project Research Grants from

References (110)

  • N. Miyashita et al.

    Clinical presentation of Legionella pneumonia: evaluation of clinical scoring systems and therapeutic efficacy

    J Infect Chemother

    (2017)
  • N. Miyashita et al.

    The CAP study group: multiplex PCR for the simultaneous detection of Chlamydia pneumoniae, Mycoplasma pneumoniae and Legionella pneumophila in community-acquired pneumonia study

    Respir Med

    (2004)
  • N. Miyashita et al.

    Evaluation of diagnostic usefulness of real-time PCR for detection of Chlamydophila pneumoniae in acute respiratory infections

    J Infect Chemother

    (2007)
  • N. Miyashita et al.

    Antibody responses of Chlamydophila pneumoniae pneumonia: why is the diagnosis of C. pneumoniae pneumonia difficult?

    J Infect Chemother

    (2015)
  • N. Miyashita et al.

    The atypical pathogen study group: Chlamydophila pneumoniae serology: cross-reaction with Mycoplasma pneumoniae infection

    J Infect Chemother

    (2013)
  • N. Miyashita et al.

    Rapid diagnostic method for the identification of Mycoplasma pneumoniae respiratory tract infection

    J Infect Chemother

    (2016)
  • N. Miyashita et al.

    Diagnostic sensitivity of a rapid antigen test for the detection of Mycoplasma pneumoniae: comparison with real-time PCR

    J Infect Chemother

    (2015)
  • N. Miyashita et al.

    Detection failure rate of chest radiography for the identification of nursing and healthcare-associated pneumonia

    J Infect Chemother

    (2015)
  • N. Miyashita et al.

    Is it possible to distinguish between atypical pneumonia and bacterial pneumonia?: evaluation of the guidelines for community-acquired pneumonia in Japan

    Respir Med

    (2004)
  • N. Miyashita et al.

    Diagnostic predictors of Legionella pneumonia in Japan

    J Infect Chemother

    (2018)
  • N. Miyashita et al.

    Validation of a diagnostic score model for the prediction of Legionella pneumophila pneumonia

    J Infect Chemother

    (2019)
  • N. Miyashita et al.

    The 7.5-kb common plasmid is unrelated to the drug susceptibility of Chlamydia trachomatis

    J Infect Chemother

    (2001)
  • R. Soejima et al.

    In vitro and in vivo activities of sparfloxacin and reference drugs against Chlamydia pneumoniae

    J Infect Chemother

    (1995)
  • N. Miyashita et al.

    In vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species

    J Infect Chemother

    (2002)
  • N. Miyashita et al.

    In vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan

    J Infect Chemother

    (2018)
  • N. Miyashita et al.

    Distribution of Legionella species and serogroups in patients with culture-confirmed Legionella pneumonia

    J Infect Chemother

    (2020)
  • K. Izumikawa et al.

    Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: postmarketing surveillance in Japan

    J Infect Chemother

    (2014)
  • K. Izumikawa et al.

    Efficacy and safety of garenoxacin tablets on clinically diagnosed bacterial pneumonia: postmarketing surveillance in Japan

    J Infect Chemother

    (2014)
  • N. Miyashita et al.

    The atypical pathogen study group: macrolide-resistant Mycoplasma pneumoniae in adults with community-acquired pneumonia

    Int J Antimicrob Agents

    (2010)
  • N. Miyashita et al.

    Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients with over 18 years

    J Infect Chemother

    (2011)
  • N. Miyashita et al.

    Transmission of macrolide-resistant Mycoplasma pneumoniae within a family

    J Infect Chemother

    (2013)
  • N. Miyashita et al.

    Atelectasis caused by macrolide-resistant Mycoplasma pneumoniae pneumonia in an adult patient

    J Infect Chemother

    (2013)
  • N. Miyashita et al.

    An association of an antibody against Chlamydia pneumoniae and coronary heart disease observed in Japan

    Eur Heart J

    (1998)
  • N. Miyashita et al.

    Association of chronic infection of Chlamydia pneumoniae and coronary heart disease in the Japan

    Intern Med

    (1998)
  • N. Miyashita et al.

    Seroprevalence of antibodies to Chlamydia spp. in human immunodeficiency virus-infected subjects in Japan

    Microbiol Immunol

    (2000)
  • Q. Hao et al.

    Chlamydia pneumoniae infection associated with enhanced MRI-spinal lesions in multiple sclerosis

    Mult Scler

    (2002)
  • T. Matsushima et al.

    Etiology and management of community-acquired pneumonia in Asia

    Curr Opin Infect Dis

    (2002)
  • N. Okimoto et al.

    Q fever in acute respiratory infection

    Kawasaki Med J

    (2016)
  • N. Miyashita et al.

    Community-acquired Chlamydia pneumoniae pneumonia

    Chest

    (2000)
  • N. Miyashita et al.

    Chlamydia pneumoniae infection during an influenza virus A epidemic: preliminary report

    J Med Microbiol

    (2000)
  • N. Miyashita et al.

    The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations

    Intern Med

    (2006)
  • T. Matsushima et al.

    The Japanese respiratory society guidelines for the management of community-acquired pneumonia in adults

    Respirology

    (2006)
  • N. Miyashita et al.

    Outbreak of Chlamydia pneumoniae infection in long-term care facilities and an affiliated hospital

    J Med Microbiol

    (2005)
  • N. Miyashita et al.

    Clinical features and the role of atypical pathogens in nursing and healthcare-associated pneumonia (NHCAP): differences between teaching university hospital and community hospital

    Intern Med

    (2012)
  • S. Kohno et al.

    The Japanese respiratory society guidelines for the management of hospital-acquired pneumonia in adults

    Respirology

    (2009)
  • N. Miyashita et al.

    Community-acquired pneumonia in Japan: a prospective ambulatory and hospitalized patient study

    J Med Microbiol

    (2005)
  • N. Miyashita et al.

    Recurrent pneumonia due to persistent Chlamydia pneumoniae infection

    Intern Med

    (2002)
  • N. Miyashita et al.

    Continuous isolation and characterization of Chlamydia pneumoniae from a patient with diffuse panbronchiolitis

    Microbiol Immunol

    (1996)
  • N. Miyashita et al.

    Chlamydia pneumoniae and asthma. Recent research developments in allergy

    Asthma & Immunology

    (2001)
  • N. Miyashita et al.

    The morphology of Chlamydia pneumonaie

    J Med Microbiol

    (1993)
  • Cited by (26)

    View all citing articles on Scopus
    View full text